ELOX
Income statement / Annual
Last year (2022), Eloxx Pharmaceuticals, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2022, Eloxx Pharmaceuticals, Inc.'s net income was -$36.07 M.
See Eloxx Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
FY-2014
|
FY-2013
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
06/30/2017 |
06/30/2016 |
06/30/2015 |
06/30/2014 |
| Operating Revenue |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$75,000.00
|
$75,000.00
|
$100,000.00
|
| Cost of Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Gross Profit |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$75,000.00 |
$75,000.00 |
$100,000.00 |
| Gross Profit Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
1 |
1 |
1 |
| Research and Development
Expenses |
$23.73 M
|
$45.57 M
|
$14.59 M
|
$26.35 M
|
$20.49 M
|
$16.40 M
|
$733,661.00
|
$2.18 M
|
$4.57 M
|
$3.34 M
|
| General & Administrative
Expenses |
$10.69 M
|
$20.45 M
|
$14.85 M
|
$24.21 M
|
$26.48 M
|
$2.70 M
|
$1.46 M
|
$1.41 M
|
$2.74 M
|
$2.61 M
|
| Selling & Marketing
Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General &
Administrative Expenses |
$10.69 M
|
$20.45 M
|
$14.85 M
|
$24.21 M
|
$26.48 M
|
$2.70 M
|
$1.46 M
|
$1.41 M
|
$2.74 M
|
$2.61 M
|
| Other Expenses |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Operating Expenses |
$34.42 M |
$66.02 M |
$29.44 M |
$50.56 M |
$46.97 M |
$19.10 M |
$2.14 M |
$3.79 M |
$7.74 M |
$7.02 M |
| Cost And Expenses |
$34.42 M |
$66.02 M |
$29.44 M |
$50.56 M |
$46.97 M |
$19.10 M |
$2.14 M |
$3.79 M |
$7.74 M |
$7.02 M |
| Interest Income |
$274,000.00 |
$8,000.00 |
$337,000.00 |
$1.07 M |
$601,000.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Interest Expense |
$1.95 M |
$1.26 M |
$1.41 M |
$1.62 M |
$7,000.00 |
$43,000.00 |
$265,203.00 |
$533.00 |
$2,767.00 |
$77,438.00 |
| Depreciation &
Amortization |
$695,000.00
|
$960,000.00
|
$571,000.00
|
$559,000.00
|
$216,000.00
|
$39,000.00
|
$44,075.00
|
$93,394.00
|
$177,074.00
|
$349,656.00
|
| EBITDA |
-$33.37 M
|
-$66.02 M
|
-$33.46 M
|
-$50.56 M
|
-$46.15 M
|
-$20.39 M
|
-$4.59 B
|
-$8.85 M
|
-$17.88 M
|
-$8.80 M
|
| EBITDA Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-48.28 |
-99.82 |
-65.72 |
| Operating Income Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-149.27
|
-241.02
|
-91.48
|
| Total Other
Income/Expenses Net |
-$1.65 M
|
-$709,000.00
|
-$1.12 M
|
-$319,000.00
|
$502,000.00
|
-$824,000.00
|
-$2.24 M
|
$2.25 M
|
$12,951.00
|
-$77,438.00
|
| Income Before Tax |
-$36.07 M |
-$66.73 M |
-$34.58 M |
-$50.87 M |
-$47.06 M |
-$21.21 M |
-$6.84 M |
-$8.95 M |
-$18.06 M |
-$9.23 M |
| Income Before Tax Ratio
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
-119.31
|
-240.85
|
-92.25
|
| Income Tax Expense |
$0.00 |
$1.26 M |
$1.41 M |
$1.62 M |
$122,000.00 |
$43,000.00 |
-$1.04 M |
-$680,000.00 |
$2,767.00 |
$77,438.00 |
| Net Income |
-$36.07 M |
-$66.73 M |
-$34.58 M |
-$50.87 M |
-$47.19 M |
-$21.21 M |
-$5.80 M |
-$8.27 M |
-$18.06 M |
-$9.23 M |
| Net Income Ratio |
0 |
0 |
0 |
0 |
0 |
0 |
0 |
-110.24 |
-240.85 |
-92.25 |
| EPS |
-16.65 |
-38.15 |
-34.47 |
-53.46 |
-58.19 |
-170.52 |
-199.71 |
-325.47 |
-1002.37 |
-1347.73 |
| EPS Diluted |
-16.65 |
-38.15 |
-34.47 |
-53.46 |
-58.19 |
-170.52 |
-199.71 |
-325.47 |
-1002.37 |
-1347.73 |
| Weighted Average Shares
Out |
$2.17 M
|
$1.75 M
|
$1.00 M
|
$951,579.00
|
$810,912.00
|
$124,409.00
|
$29,024.00
|
$25,403.00
|
$18,021.00
|
$6,845.00
|
| Weighted Average Shares
Out Diluted |
$2.17 M
|
$1.75 M
|
$1.00 M
|
$951,579.00
|
$810,912.00
|
$124,409.00
|
$29,024.00
|
$25,403.00
|
$18,021.00
|
$6,845.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
